References
- Arnold, A. Z., Mick, M. J., Mazurek, R. P., Loop, F. D., Trohman, R. G. (1992). Role of prophylactic anticoagulation for direct current cardioversion in patients with atrial fibrillation or atrial flutter. J. Amer. Coll. Cardiol., 19, 851–855.
- Camm, A. J., Savelieva, I. (2014) Practical considerations for using novel oral anticoagulants in patients with atrial fibrillation. Clin. Cardiol., 37 (1), 32–47.
- Cannon, C. P., Armani, A. M. (2008). Atrial Fibrillation – From Bench to Bedside. Humana Press. 46 pp.
- Chugh, S. S., Havmoeller, R., Narayanan, K., Singh, D., Rienstra, M., Benjamin, E. J., Gillum, R. F., Kim, Y. H., McAnulty, J. H. Jr., Zheng, Z. J., Forouzanfar, M. H., Naghavi, M., Mensah, G. A., Ezzati, M., Murray, C. J. (2014). Worldwide epidemiology of atrial fibrillation: A Global Burden of Disease 2010 Study. Circulation, 129, 837–847.
- Femia, G., Fetahovic, T., Shetty, P., Lee, A. (2017). Novel oral anticoagulants in direct current cardioversion for atrial fibrillation. Heart Lung Circ., 27 (7), 798–803.
- Go, A. S., Mozaffarian, D., Roger, V. L., Benjamin, E. J, Berry, J. D., Blaha, M. J., Dai, S., Ford, E. S., Fox, C. S., Franco, S., Fullerton, H. J., Gillespie, C., Hailpern, S. M., Heit, J. A., Howard, V. J., Huffman, M. D., Judd, S. E., Kissela, B. M., Kittner, S. J., Lackland, D. T., Lichtman, J. H., Lisabeth, L. D., Mackey, R. H., Magid, D. J., Marcus, G. M., Marelli, A., Matchar, D. B., McGuire, D. K., Mohler, E. R. 3rd., Moy, C. S., Mussolino, M. E., Neumar, R. W., Nichol, G., Pandey, D. K., Paynter, N. P., Reeves, M. J., Sorlie, P. D., Stein, J., Towfighi, A., Turan, T. N., Virani, S. S., Wong, N. D., Woo, D., Turner, M. B. (2014). American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation, 129, e28–e292.
- Hart, R. G., Pearce, L. A., Aguilar, M. I. (2007). Meta-analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann. Intern. Med.,146, 857–867.
- Heidbuchel, H., Verhamme, P., Alings, M., Antz, M., Diener, H. C., Hacke, W., Oldgren, J., Sinnaeve, P., Camm, A. J., Kirchhof, P. (2017). Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Eur. Heart J., 38 (27), 2137–2149.
- Kirchhof, P., Benussi, S., Kotecha, D., Ahlsson, A., Atar, D., Casadei, B., Castellá, M., Diener, H. C., Heidbuchel, H., Hendriks, J., Hindricks, G., Manolis, A. S., Oldgren, J., Alexandru, P. B., Schotten, U., Van P. B., Vardas, P. (2016). 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. The Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Eur. Heart J., 37, 2893–2962.
- Kirchhof, P., Monnig, G., Wasmer, K., Heinecke, A., Breithardt, G., Eckardt, L., Bocker, D. (2005) A trial of self-adhesive patch electrodes and hand-held paddle electrodes for external cardioversion of atrial fibrillation (MOBIPAPA). Eur. Heart J., 26, 1292–1297.
- Lloyd-Jones, D. M.,Wang, T. J., Leip, E. P., Larson, M. G., Levy, D., Vasan, R. S., D’Agostino, R. B., Massaro, J. M., Beiser, A., Wolf, P. A., Benjamin, E. J. (2004). Lifetime risk for development of atrial fibrillation: The Framingham Heart Study. Circulation, 110, 1042–1046.
- Nuotio, I., Hartikainen, J. E., Grönberg, T., Biancari, F., Airaksinen, K. E. (2014). Time to cardioversion for acute atrial fibrillation and thromboembolic complications. JAMA,312, 647–649.
- Olesen, J. B., Sørensen, R., Hansen, M. L., Lamberts, M., Weeke, P., Mikkelsen, A. P., Køber, L., Gislason, G. H., Torp-Pedersen, C., Fosbøl, E. L. (2015). Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naive atrial fibrillation patients: Danish nationwide descriptive data 2011–2013. Europace, 17 (2), 187–193.
- Ott, A., Breteler, M. M., de Bruyne, M. C., van Harskamp, F., Grobbee, D. E., Hofman, A. (1997). Atrial fibrillation and dementia in a population-based study. The Rotterdam Study. Stroke, 28, 316–321.
- Pisters, R., Nieuwlaat, R., Prins, M. H., Le Heuzey, J. Y., Aldo, P., Maggioni, A., Camm, A. J., Crijns, H. J. (2012). Clinical correlates of immediate success and outcome at 1-year follow-up of real-world cardioversion of atrial fibrillation: The Euro Heart Survey. Europace, 5 (14), 666–674.
- Pupkevica, I., Lituņenko, O., Vīnkalna, I., Strēlnieks, A., Šime, I., Stirna, V., Kovaļova, M., Rancāne, R., Miglāne, E., Tilgale, B., Trušinskis, K., Kalējs, O., Lejnieks, A. (2014). Risk of cardiovascular events in patients with atrial fibrillation after electrical cardioversion. RSU Scientific Articles,4,122–137.
- Singh, S. N., Tang, X. C., Reda, D., Singh, B. N. (2009). Systematic electrocardioversion for atrial fibrillation and role of antiarrhythmic drugs: A substudy of the SAFE-T trial. Heart Rhythm, 6 (2), 152–155.
- Stampfuss, J., Kubitza, D., Becka, M., Mueck, W. (2013). The effect of food on the absorption and pharmacokinetics of rivaroxaban. Int. J. Clin. Pharmacol. Ther., 51 (7), 549–561.
- Stewart, S., Murphy, N., Walker, A., McGuire, A., McMurray, J. J. V. (2004). Cost of an emerging epidemic: An economic analysis of atrial fibrillation in the UK. Heart, 90, 286–292
- Strēlnieks, A., Vīnkalna, I., Lituņenko, O., Pupkevica, I., Šime, I., Vikmane, M., Kovaļova, M., Rancāne, M., Dormidontova, G., Sakne, S., Pudulis, J., Mintāle, I., Kalējs, O., Lejnieks, A. (2014). Atrial fibrillation and risk factors of recurrent paroxysms after electrical cardioversion. RSU Scientific Articles,4, 137–157.
- Sucu, M., Davutoglu, V., Ozer, O. (2009). Electrical cardioversion. Annu. Saudi Med., 29 (3), 201–206.
- Weinberg, D. M., Mancini, J. (1989). Anticoagulation for cardioversion of atrial fibrillation. Amer. J. Cardiol., 63, 745–746.
- Wolf, P. A., Abbott, R. D., Kannel, W. B. (1991). Atrial fibrillation as an independent risk factor for stroke: The Framingham Study. Stroke, 22, 983–988.
- Xiong, Q., Proietti, M., Senoo, K., Lip, G. Y. (2015). Asymptomatic versus symptomatic atrial fibrillation: A systematicreview of age/gender differences and cardiovascular outcomes. Int. J. Cardiol., 191, 172–177.